Get the Stockscreener App
828.50
0.66%
-5.54
After Hours:
828.50
Regeneron Pharmaceuticals Inc stock is traded at $828.50, with a volume of 671.94K.
It is down -0.66% in the last 24 hours and up +26.29% over the past month.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.
See More
Previous Close:
$834.04
Open:
$834.51
24h Volume:
671.94K
Relative Volume:
0.72
Market Cap:
$85.30B
Revenue:
$14.92B
Net Income/Loss:
$4.42B
P/E Ratio:
20.19
EPS:
41.0422
Net Cash Flow:
$3.79B
1W Performance:
+2.80%
1M Performance:
+26.29%
6M Performance:
+7.29%
1Y Performance:
+40.55%
1-Day Range:
$823.39
$834.70
1-Week Range:
$805.93
$847.00
52-Week Range:
$541.00
$847.00
Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile
Name
Regeneron Pharmaceuticals Inc
Sector
Industry
Phone
(914) 847-7000
Address
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Compare REGN vs VRTX, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
REGN
Regeneron Pharmaceuticals Inc
|
828.50 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
VRTX
Vertex Pharmaceuticals Inc
|
547.59 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
ARGX
Argen X Se Adr
|
1,011.11 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
138.89 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
211.58 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-31-26 | Resumed | Piper Sandler | Overweight |
| Mar-06-26 | Initiated | Barclays | Overweight |
| Jan-07-26 | Upgrade | BofA Securities | Underperform → Buy |
| Dec-03-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-24-25 | Initiated | HSBC Securities | Buy |
| Nov-24-25 | Resumed | Truist | Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Perform |
| Aug-14-25 | Initiated | Rothschild & Co Redburn | Buy |
| Jun-30-25 | Downgrade | Argus | Buy → Hold |
| May-30-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| May-30-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| May-14-25 | Upgrade | Citigroup | Neutral → Buy |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Overweight |
| Feb-05-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Jan-16-25 | Downgrade | UBS | Buy → Neutral |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Sep-24-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Mar-12-24 | Initiated | Bernstein | Outperform |
| Jan-12-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-03-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Aug-21-23 | Upgrade | Canaccord Genuity | Hold → Buy |
| Aug-21-23 | Reiterated | Oppenheimer | Perform |
| Jun-28-23 | Downgrade | Canaccord Genuity | Buy → Hold |
| Mar-27-23 | Upgrade | SVB Securities | Market Perform → Outperform |
| Mar-24-23 | Upgrade | Jefferies | Hold → Buy |
| Mar-23-23 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Jan-30-23 | Upgrade | Cowen | Market Perform → Outperform |
| Jan-20-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-26-22 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Oct-17-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Sep-09-22 | Upgrade | Jefferies | Underperform → Hold |
| Sep-09-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jul-25-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Neutral |
| Jun-06-22 | Initiated | Jefferies | Underperform |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Jan-05-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Jan-03-22 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Dec-15-21 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Dec-09-21 | Resumed | Wells Fargo | Overweight |
| Dec-07-21 | Resumed | Cowen | Market Perform |
| Dec-06-21 | Initiated | Goldman | Buy |
| Nov-19-21 | Resumed | BMO Capital Markets | Outperform |
| Nov-05-21 | Downgrade | The Benchmark Company | Buy → Hold |
| Jun-29-21 | Initiated | H.C. Wainwright | Buy |
| Jan-25-21 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jan-13-21 | Upgrade | The Benchmark Company | Hold → Buy |
| Jan-08-21 | Upgrade | Citigroup | Neutral → Buy |
| Oct-05-20 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Aug-20-20 | Downgrade | The Benchmark Company | Buy → Hold |
| Jul-09-20 | Upgrade | SunTrust | Hold → Buy |
| May-26-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Apr-28-20 | Downgrade | Citigroup | Buy → Neutral |
| Apr-17-20 | Upgrade | The Benchmark Company | Hold → Buy |
| Apr-08-20 | Initiated | The Benchmark Company | Hold |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Feb-26-20 | Upgrade | Canaccord Genuity | Hold → Buy |
| Feb-26-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Feb-25-20 | Upgrade | Jefferies | Hold → Buy |
| Feb-11-20 | Upgrade | Argus | Hold → Buy |
| Dec-24-19 | Initiated | Raymond James | Mkt Perform |
| Dec-16-19 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-13-19 | Upgrade | Credit Suisse | Neutral → Outperform |
| Nov-12-19 | Initiated | SunTrust | Hold |
| Nov-07-19 | Upgrade | Citigroup | Neutral → Buy |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Sep-23-19 | Upgrade | Guggenheim | Neutral → Buy |
View All
Regeneron Pharmaceuticals Inc Stock (REGN) Latest News
Regeneron Pharmaceuticals (REGN) Wins Pasatru Approval, Is The Upside Already Priced In? - simplywall.st
Did You Lose Money on Regeneron Pharmaceuticals, Inc. (REGN)? Levi & Korsinsky Urges Investors to Act Before September 14, 2026 - ACCESS Newswire
IBBQ vs. PBE: Which Biotech ETF Is the Better Buy? - The Motley Fool
Why Is Regeneron (NASDAQ:REGN) Drawing Attention After Market Drop? - Kalkine Media
Wealthfront Advisers LLC Invests $4.37 Million in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron stock holds above $826 as FDA approval and lawsuit reshape risk picture - Ad-hoc-news.de
Tocqueville Asset Management L.P. Acquires Shares of 3,315 Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Madison Asset Management LLC Takes Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Ceredex Value Advisors LLC Acquires New Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Diversify Advisory Services LLC Buys New Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals (NASDAQ:REGN) Enters New Healthcare Focus - Kalkine Media
Regeneron stock jumps on FDA approval for ultra-rare bone disorder drug - Ad-hoc-news.de
REGN Shareholder Alert: September 14, 2026 Lead Plaintiff Deadline in Regeneron Pharmaceuticals Securities Class ActionContact SueWallSt - Morningstar
Advanz Looks To Nix Regeneron, Bayer Eye Med Patents - Law360
Regeneron Pharmaceuticals (REGN) Wins FDA Approval For The First Adult FOP Treatment - simplywall.st
Regeneron to challenge Ipsen as FDA clears bone disease drug - BioPharma Dive
Regeneron Secures FDA Approval for Rare Genetic Disorder Drug - Yahoo Finance
REGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regeneron Pharmaceuticals, Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
REGN Looks 5.6% Undervalued on GF Value™ Amid FDA Approval Boost - GuruFocus
REGN Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Regeneron Pharmaceuticals Securities LawsuitContact Levi & Korsinsky - Business Wire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Regeneron Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming DeadlinesREGN - PR Newswire
Regeneron Pharmaceuticals, Inc. (REGN) Investors: September 14, 2026 Lead Plaintiff Deadline in Class Action Lawsuit - PR Newswire
Regeneron Secures FDA Approval For Ultra-Rare Bone Disorder Drug - Benzinga
REGENERNON PHARMACEUTICALS, INC. (REGN) SHAREHOLDER ALERT - GlobeNewswire
FDA nod for Regeneron’s Pasatru for ultra-rare genetic disorder FOP - The Pharma Letter
Johnson Financial Group Inc. Buys Shares of 3,250 Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
1,311 Shares in Regeneron Pharmaceuticals, Inc. $REGN Purchased by Meeder Advisory Services Inc. - MarketBeat
E Fund Management Co. Ltd. Makes New $3.22 Million Investment in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
DCF Advisers LLC Purchases New Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
US FDA approves Regeneron's rare bone disorder drug - Reuters
Regeneron (REGN) Stock Looks Undervalued On Expanded Cancer Collaboration News - Yahoo Finance
REGN Stockholders Interested in Leading the Class Action Against Regeneron Pharmaceuticals, Inc. Should Contact Robbins LLP for Information About Recovering Their Losses - Morningstar
Regeneron (REGN) Results Review: Profit Per Share Clears Its Benchmark in the Current Update; Closing Reaction - Vinanet
TLX: Revenue up 22% to $477.3M, net profit $38.3M, boosted by U.S. sales and Regeneron deal - TradingView
US FDA approves Regeneron’s rare bone disorder drug - KELO-AM
Ninth Circuit Revives Regeneron Kickback Whistleblower Lawsuit - Bloomberg Law News
Pasatru’s FDA Approval Puts Regeneron’s Rare-Disease Playbook To The Test - insights.citeline.com
Regeneron Announces Investor Conference Presentations - marketscreener.com
Why Does Regeneron Pharmaceuticals (NASDAQ:REGN) Merit A Fresh Look? - Kalkine Media
REGN Looks 4.9% Undervalued on GF Value™ After FDA Approval - GuruFocus
Regeneron Pharmaceuticals Wins US FDA Approval For Pasatru In Ultra-Rare Musculoskeletal Condition - marketscreener.com
FDA approves Regeneron’s Pasatru for rare bone disorder FOP - Investing.com
FDA approves Regeneron’s Pasatru for rare bone disorder FOP By Investing.com - Investing.com Canada
Regeneron Pharmaceuticals Announces FDA Approval of Pasatru for Adults With Fibrodysplasia Ossificans Progressiva - Quiver Quantitative
Regeneron rare bone disorder therapy approved (REGN:NASDAQ) - Seeking Alpha
REGN Investor Alert: Regeneron Pharmaceuticals, Inc. Securities Class Action NoticeContact Levi & Korsinsky - PR Newswire
Bronstein, Gewirtz & Grossman LLC Urges Regeneron - GlobeNewswire
Regeneron Pharmaceuticals (NASDAQ:REGN) Reaches New 52-Week HighWhat's Next? - MarketBeat
Regeneron Pharmaceuticals stock hits 52-week high at 821.41 USD By Investing.com - Investing.com Australia
Regeneron Pharmaceuticals stock hits 52-week high at 821.41 USD - Investing.com
REGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regeneron Pharmaceuticals, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Regeneron Pharmaceuticals Inc Stock (REGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.76%
1.01%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):